Previous 10 | Next 10 |
Daniel Loeb's Third Point hedge fund says it cut its stake in United Technologies ( UTX +1% ), becoming the second activist hedge fund to sell shares following the merger announcement with Raytheon. More news on: United Technologies Corporation, Tradeweb Markets Inc., American Express ...
Introduction I've only had time to do three Q2 articles on biotechs, including Edwards ( EW ) in that category. In this article, I'll therefore present some comments on stocks which I have not written about in a few months or longer, as well a brief update on my largest biotech holding, Merc...
This article is part of a series that provides an ongoing analysis of the changes made to David Abrams’ 13F portfolio on a quarterly basis. It is based on Abrams’ regulatory 13F Form filed on 08/09/2019. Please visit our Tracking David Abrams’ Abrams Capital Management ...
As the Celgene ( CELG ) acquisition heads towards closure, investors need to position themselves for owning shares in the new Bristol-Myers Squibb ( BMY ). The cash and stock transaction positions the long-term value of the merger in owning BMY stock, requiring investors to have a plan f...
Athenex ( ATNX -29.9% ) slumps on more than triple normal volume following its release of topline data from a Phase 3 clinical trial evaluating oral paclitaxel (Oraxol) compared to the intravenous formulation [Celgene's ( CELG -0.1% ) Abraxane] in patients with metastatic breast canc...
Merger activity decreased last week with three new deals announced and ten pending deals closing. Deal Statistics: New Deals: The acquisition of Genomic Health ([[GHDX]]) by Exact Sciences Corporation ([[EXAS]]) for $2.8 billion in a cash-plus-stock deal. Under the terms of the ...
Disneyland will never be completed. It will continue to grow as long as there is imagination left in the world." - Walt Disney For the most part, the second quarter saw a continuation of the first quarter's positive performance across many asset classes. This furthered a reversal o...
It's fairly rare that I pound the table for a specific stock because I'm happy to acknowledge that the market is unpredictable, and there are no sure things in the equity space. However, from time to time I see value that is so compelling that I can't help but hype up a potential investment op...
Jounce Therapeutics ( JNCE ) established an updated deal with its partner Celgene ( CELG ). The new deal consists of a total amount of $530 million in potential payments, but it replaces an old deal established back in 2016 worth a potential $2.6 billion. Still, it is good to see tha...
The following slide deck was published by Celgene Corporation in conjunction with their 2019 Q2 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Celgene Corporation Company Name:
CELG Stock Symbol:
NASDAQ Market:
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...